Python Molecule Spurs Weight Loss in Mice—Potential New Obesity Drug?

The remarkable metabolic feats of Burmese pythons – consuming prey equivalent to their own weight and then fasting for months – may hold a key to new obesity treatments, scientists have discovered. A newly identified molecule, significantly elevated in python blood after a large meal, appears to suppress appetite in mice, leading to substantial weight loss without some of the common side effects associated with existing medications.

Researchers at Stanford University and the University of Colorado Boulder have been investigating the physiological changes pythons undergo during and after feeding. These snakes exhibit a dramatic surge in metabolism, with their heart rate increasing by 25% and metabolic rate accelerating 4,000-fold to process a massive meal. They can then survive for extended periods – 12 to 18 months – without eating, a metabolic flexibility rarely seen in mammals.

Uncovering pTOS: A Molecule of Metabolic Adaptation

The study, published in Nature Metabolism, initially focused on the rapid heart growth observed in pythons after feeding. Researchers examined blood samples from young Burmese pythons (weighing 1.5-2.5kg) before and after they consumed a meal representing approximately 25% of their body weight, following a 28-day fast. Analysis revealed over 200 molecules that increased in concentration after feeding, with one – dubbed pTOS – increasing more than 1,000-fold. Interestingly, pTOS is also present, albeit at low levels, in human urine.

“We wondered whether this metabolite affected any of the post-feeding physiological changes in the snake,” explained Dr. Jonathan Long, an associate professor of pathology at Stanford University and co-author of the research. The team then tested the effects of pTOS on laboratory mice.

Appetite Suppression in Mice: A Potential Pathway for Obesity Treatment

Surprisingly, administering pTOS to mice did not significantly impact energy expenditure or organ size. However, it profoundly altered their eating behavior. Mice treated with pTOS consumed considerably less food than control groups and experienced a 9% reduction in body weight over 28 days. This suggests pTOS primarily targets appetite regulation, rather than directly influencing metabolism.

This mechanism of action differs from that of GLP-1 receptor agonists like Wegovy and Ozempic, currently popular weight-loss medications. GLP-1 drugs gradual gastric emptying, promoting a feeling of fullness, but can also cause side effects like nausea and constipation. PTOS, in contrast, appears to act on the hypothalamus, a brain region central to appetite control. This difference is significant, as it suggests a potential for developing appetite suppressants with fewer gastrointestinal side effects. You can find more information about GLP-1 medications here.

The Python as a Model for Extreme Physiology

The use of pythons as a model for studying extreme physiological adaptations is gaining traction in the scientific community. As noted by Professor Leslie Leinwand, a biologist at the University of Colorado Boulder and a co-author of the study, “We’ve basically discovered an appetite suppressant that works in mice without some of the side-effects that GLP-1 drugs have.” Leinwand’s research group has been studying pythons for over two decades, recognizing their unique ability to handle massive fluctuations in metabolic demand. The utility of Burmese pythons in modeling physiological plasticity is highlighted in recent research.

The ability of pythons to thrive after consuming prey that represents a substantial portion of their body weight is a testament to their remarkable metabolic flexibility. This involves not only a surge in metabolism but also a complex interplay of hormonal and molecular signals. Understanding these signals could provide valuable insights into metabolic regulation in other species, including humans.

Limitations and Future Research

While the findings are promising, it’s crucial to acknowledge the limitations of the study. The research was conducted on mice, and the effects of pTOS in humans remain unknown. Further investigation is needed to determine whether pTOS has similar effects on human appetite and metabolism, and to assess its safety and efficacy as a potential therapeutic agent. The study also focused on young pythons; it’s unclear whether the same metabolic pathways are active in older snakes.

The fact that pTOS occurs naturally in humans is encouraging, suggesting it may be well-tolerated. However, rigorous clinical trials will be necessary to confirm its safety and effectiveness before it can be considered for use in obesity treatment. Researchers are also exploring the role of gut bacteria in pTOS production, as this could offer additional avenues for therapeutic intervention. The initial research focused on identifying the metabolites involved in heart growth, but the appetite-suppressing effect of pTOS emerged as a particularly intriguing finding.

What’s Next: From Lab to Clinical Trials?

The next steps involve further preclinical studies to refine our understanding of pTOS’s mechanism of action and to optimize its delivery. Researchers will also require to investigate potential interactions between pTOS and other medications. If these studies are successful, the ultimate goal is to initiate clinical trials in humans to evaluate the safety and efficacy of pTOS as a treatment for obesity. The process of translating these findings into a viable therapy will likely take several years, but the potential benefits are significant. The team is also exploring whether similar metabolites exist in other animals known for their metabolic resilience, such as hibernating mammals.